Overview

Evidence from real world studies on the effectiveness, safety, and dosing of non-vitamin-K oral anticoagulants (NOACs) provides crucial insights on the treatment of patients with atrial fibrillation (AF). In this program, you will learn to assess the quality of these studies and compare the relevance, validity, and utility of the results to those of randomized controlled trials. Judicial assessment and appropriate incorporation of real world data into clinical practice can improve the care of your patients with AF and other conditions.

Learning Objectives

  • Explain the differences between RCTs and real world studies, including the study setting, type of data being evaluated, and utility of the results
  • Describe methodologies that contribute to high-quality real world studies
  • Describe recent real world studies about NOAC effectiveness, safety, and dosing, and recognize how these studies can inform clinical care

Faculty

Lawrence Blonde, MD, FACP, MACE

Director, Ochsner Diabetes Clinical Research Unit
Frank Riddick Diabetes Institute
Department of Endocrinology
Ochsner Medical Center
New Orleans, LA 

Ty J. Gluckman, MD, FACC, FAHA

Medical Director
Center for Cardiovascular Analytics, Research and Data Science (CARDS)
Providence Heart Institute
Providence St. Joseph Health
Portland, OR 

Pamela Kushner, MD, FAAFP

Director
Kushner Wellness Center
Clinical Professor
University of California at Irvine
Orange, CA 

Disclosures

The following financial relationships have been disclosed by faculty: 

Lawrence Blonde, MD, FACP, MACE
Contracted Research for AstraZeneca; Janssen Pharmaceuticals, Inc.; Lexicon Pharmaceuticals, Inc.; Merck & Co., Inc.; Novo Nordisk Inc.; and Sanofi US. Consultant for AstraZeneca; GlaxoSmithKline; Intarcia Therapeutics, Inc.; Janssen Pharmaceuticals, Inc., Merck & Co., Inc.; Novo Nordisk Inc.; and Sanofi US. Services Provided for Promotional Purposes (not for CME/CE Services) for AstraZeneca; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novo Nordisk Inc.; and Sanofi US.

Ty J. Gluckman, MD, FACC, FAHA
No financial relationships to disclose. 

Pamela Kushner, MD, FAAFP 
Advisory Board and Speaker's Bureau for AstraZeneca; GlaxoSmithKline; and Janssen Pharmaceuticals, Inc. Consultant for AstraZeneca and Janssen Pharmaceuticals. 

 

Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.

CME/CE Information

AMA PRA Category 1 Credits

Accreditation Statement

pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Designation Statement

pmiCME designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP

Accreditation Statement

pmiCME is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider Number 040308.


Designation Statement

This program has been approved for 1.00 contact hour of continuing education, which includes 0.38 hour of pharmacology.

MOC Credit Information

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 


Commercial Supporter

Bristol-Myers Squibb and Pfizer Alliance

Education Partner

pmiCME


Fine Print

Internet Explorer (version 9.0 and above) is the minimum supported browser for Pri-Med Online eCME activities. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection (DSL, cable modem, or LAN-based) is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, pmiCME, pmiCME Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

pmiCME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of pmiCME to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

pmiCME Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. pmiCME, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. pmiCME is the accredited provider for this activity.

Disclosures and Conflict of Interest
pmiCME requires all individuals in a position to influence educational content for pmiCME-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. pmiCME assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by pmiCME or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.